Leerink Partners analyst Joseph Schwartz has maintained their neutral stance on PTCT stock, giving a Hold rating on October 11. Joseph

PTC Therapeutics has suffered another setback in its bid to keep its Duchenne muscular dystrophy drug Translarna on the market in Europe. PTC on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has once again recommended against renewal of the conditional marketing authorization for Translarna.

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has maintained its negative opinion on the renewal of the conditional marketing authorization of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne Muscular Dystrophy (nmDMD) following re-examination.

PTC Therapeutics (PTCT) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has